Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH 2 study

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2747-2752

  Mégraud, Francis ^a   Lehn, Norbert ^b   Lind, Tore ^d   Bayerdörffer, Ekkehard ^c   O'Morain, Colm ^g   Spiller, Robin ^h   Unge, Peter ^e   Veldhuyzen Van Zanten, Sander ⁱ   Wrangstadh, Michael ^f   Burman, Carl Fredrik ^f  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d Kärnsjukhuset ^*  (Sweden)

^e Sandviken Animal Hospital   (Sweden)

^f ASTRAZENECA R AND D   (Sweden)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

^h QUEEN S MEDICAL CENTRE   (United Kingdom)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; UREA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIUM CULTURE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERADICATION THERAPY; EUROPE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH BIOPSY;

EID: 0345109242     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2747     Document Type: Article

References (40)

1. Barthel, J. S., and E. D. Everett. 1990. Diagnosis of Campylobacter pylori infections: the "gold standard" and the alternatives. Rev. Infect. Dis. 12(Suppl. 1):S107-S114.
2. Bouchard, S., C. Birac, H. Lamouliatte, S. Forestier, and F. Mégraud. 1996. Correlation between the MICs of metronidazole on H. pylori strains and the outcome of a lansoprazole-amoxicillin-metronidazole therapy. Gut 39(Suppl. 2):A05. (Abstract.)
3. Buckley, M. J. M., H. X. Xia, D. M. Hyde, C. T. Keane, and C. O'Morain. 1997. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig. Dis. Sci. 42:2111-2115.
4. Cederbrant, G., G. Kahlmeter, and A. Ljungh. 1992. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 29:115-120.
5. Cederbrant, G., G. Kahlmeter, and A. Ljungh. 1993. The Etest for antimicrobial susceptibility testing of Helicobacter pylori. J. Antimicrob. Chemother. 31:65-71.
6. Dent, J. C., and C. A. McNulty. 1988. Evaluation of a new selective medium for Campylobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 7:555-558.
7. Dore, M. P., M. S. Osato, G. Realdi, I. Mura, D. Y. Graham, and A. R. Sepulveda. 1999. Amoxicillin tolerance in Helicobacter pylori. J. Antimicrob. Chemother. 43:47-54.
8. Glupczynski, Y., M. Labbé, W. Hansen, F. Crokahert, and E. Yourassowsky. 1991. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J. Clin. Microbiol. 29:2072-2075.
9. Goddard, A. F., M. J. Jessa, D. A. Barrett, P. N. Shaw, J. P. Idström, C. Cederberg, and R. C. Spiller. 1996. Effect of omeprazole on the distribution of metronidazole, amoxicillin and clarithromycin in human gastric juice. Gastroenterology 111:358-367.
10. Goodwin, A., D. Kersulyte, G. Sisson, S. J. O. Veldhuyzen van Zanten, D. E. Berg, and P. S. Hoffman. 1998. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28:383-393.
11. Goodwin, C. S., B. J. Marshall, E. D. Blincow, D. H. Wilson, S. Blackbourn, and M. Philipps. 1988. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J. Clin. Pathol. 41:207-210.
12. Hachem, C. Y., J. E. Clarridge, D. G. Evans, and D. Y. Graham. 1995. Comparison of agar based media for primary isolation of Helicobacter pylori. S. Clin. Pathol. 48:714-716.
13. Hartzen, S. H., L. P. Andersen, A. Bremmelgaard, H. Colding, M. Arpi, J. Kristiansen, T. Justesen, F. Espersen, N. Frimot-Moller, and O. Bonnevie. 1997. Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time. Antimicrob. Agents Chemother. 41:2634-2639.
14. Hirschl, A. M., M. M. Hirschl, and M. L. Rotter. 1993. Comparison for the determination of the sensitivity of Helicobacter pylon to metronidazole. J. Antimicrob. Chemother. 32:45-49.
15. Kist, M., S. Strobel, U. R. Fölsch, T. Kirchner, E. G. Hahn, D. H. van Kleist, H. U. Klör. and H. G. Dammann. 1997. Prospective assessment of the impact of primary antimicrobial resistance on cure rates of Helicobacter pylori infection. Gut 41(Suppl. 1):A90.
16. Lambert, T., F. Mégraud, G. Gerbaud, and P. Courvalin. 1986. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob. Agents Chemother. 30:510-511.
17. Lerang, F., B. Moum, J. B. Haug, P. Tolas, O. Breder, E. Aubert, O. Hoie, T. Soberg, B. Flaaten, P. Farup, and T. Berge. 1997. Highly effective twice-daily triple therapies for H. pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am. J. Gastroenterol. 92:248-253.
18. Lind, T., F. Mégraud, P. Unge, E. Bayerdörffer, C. O'Morain, R. Spiller, S. V. van Zanten, K. D. Bardhan, M. Hellblom, M. Wrangstadh, L. Zeijlon, and C. Cederberg. 1999. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253.
19. Lind, T., S. V. van Zanten, P. Unge, R. Spiller, E. Bayerdörffer, C. O'Morain, K. D. Bardhan, M. Bradette, N. Chiba, M. Wrangstadh, C. Cederberg, and J. P. Idstrom. 1996. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH1 study. Helicobacter 3:138-144.
20. Marcus, R., E. Peritz, and K. R. Gabriel. 1976. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655-660.
21. Mégraud, F. 1996. Advantages and disadvantages of current diagnostic tests for the detection of Helicobacter pylori. Scand. J. Gastroenterol. 31(Suppl. 215):57-62.
22. Mégraud, F. 1996. Diagnostic bactériologique standard de l'infection à Helicobacter pylori, p. 249-276. In F. Mégraud and H. Lamouliatte (ed.), Helicobacter pylori, vol. 1. Elsevier, Paris, France.
23. Mégraud, F. 1997. How should Helicobacter pylori infection be diagnosed? Gastroenterology 113:S93-S98.
24. Mégraud, F. 1998. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 115:1278-1282.
25. Mégraud, F., F. Bonnet, M. Garnier, and H. Lamouliatte. 1985. Characterization of "Campylobacter pyloridis" by culture, enzymatic profile, and protein content. J. Clin. Microbiol. 22:1007-1010.
26. Mégraud, F., and H. P. Doermann. 1998. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 43(Suppl. 1 ):S61-S65.
27. Mégraud, F., H. Lamouliatte, S. Bouchard, C. Birac, and F. Villeval. 1991. Evaluation of a transport medium: Portagerm pylori for Helicobacter pylori, abstr. 1040. In Abstracts of the European Congress on Clinical Microbiology and Infectious Diseases.
28. Misiewicz, J. J., A. W. Harris, K. D. Bardhan, S. Levi, C. O'Morain, B. T. Cooper, G. D. Kerr, M. F. Dixon, H. Langworthy, and D. Piper. 1997. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Gut 41:735-739.
29. Moayyedi, P., D. S. Tompkins, P. L. Ragunathan, and A. T. R. Axon. 1996. Prevalence of metronidazole in predicting failure of omeprazole, clarithromycin and tinidazole to eradicate H. pylori. Gut 39(Suppl. 2):A6. (Abstract.)
30. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing. VIth informational supplement. M100S9 19, 1. National Committee for Clinical Laboratory Standards, Villanova, Pa.
31. Occhialini, A., M. Urdaci, F. Doucet-Populaire, C. M. Bébéar, H. Lamouliatte, and F. Mégraud. 1997. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob. Agents Chemother. 41:2724-2728.
32. Piccolomini, R., G. di Bonaventura, G. Catamo, F. Carbone, and M. Neri. 1997. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J. Clin. Microbiol. 35:1842-1846.
33. Smith, M. A., and D. I. Edwards. 1995. The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J. Antimicrob. Chemother. 36:453-461.
34. Tee, W., S. Fairley, R. Smallwood, and B. Dwyer. 1991. Comparative evaluation of three selective media and a nonselective medium for the culture of Helicobacter pylori from gastric biopsies. J. Clin. Microbiol. 29:2587-2589.
35. Utrup, L. J., R. Flamm, M. Osato, M. J. Ferraro, L. B. Reller, A. Barry, K. Bush, and N. Silliman. 1998. Susceptibility testing standardization and quality control ranges for Helicobacter pylori, abstr. C-31. In Program and abstracts of the 98th General Meeting of the American Society for Microbiology 1998. American Society for Microbiology, Washington, D.C.
36. van Zwet, A. A., C. M. J. E. Vanderbroucke-Grauls, E. J. ven der Wouden, M. M. Gerrits, and J. G. Kusters. 1998. Stable amoxicillin resistance in Helicobacter pylori. Lancet 352:1595.
37. Veldhuyzen van Zanten, S. J., P. T. Pollak, H. Kapoor, and P. K. Yeung. 1996. Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori. Dig. Dis. Sci. 41:1845-1852.
38. Versalovic, J., D. Shortridge, K. Kliber, V. Griffy, J. Beyer, R. K. Flamm, S. K. Tanaka, D. Y. Graham, and M. F. Go. 1996. Mutations in 23S rRNA are associated with clarithromycin resistance in Heticobacter pylori. Antimicrob. Agents Chemother. 40:477-480.
39. Westblom, T. U., S. Gudipâti, E. Madan, and B. R. Midkiff. 1991. Improved growth of Helicobacter pylori using a liquid medium supplemented with human serum. Ital. J. Gastroenterol. 23(Suppl. 2):48. (Abstract.)
40. Wurzer, H., L. Rodrigo, D. Stamler, A. Archambault, T. Rokkas, N. Skandalis, R. Fedorak, F. Bazzoli, E. Hentschel, P. Mora, A. Archimandritis, and F. Mégrand. 1997. Short-course therapy with amoxicillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group Aliment. Pharmacol. Ther. 11:943-952.